Aglatimagene Shows Extended Survival in Phase 2a Lung Cancer Trial

Candel Therapeutics has reported extended survival outcomes from its ongoing phase 2a trial of CAN-2409 in advanced non-small cell lung cancer patients who had previously shown an inadequate response to immune checkpoint inhibitors. The updated data indicate that 50% of patients remained alive at 24 months after treatment, with 35% surviving beyond 30 months. Median overall survival reached 25.4 months, which compares favorably to historical data. The company plans to initiate a pivotal phase 3 trial in the second quarter of 2026.